APR 07, 2015 10:15 PM PDT

Cancer Drug Shows Promise for Treating Stroke

WRITTEN BY: Ilene Schneider
A University of Victoria neuroscientist has discovered that a cancer drug may improve recovery rates for diabetic patients who have suffered a stroke.
The reasons behind the poorer prognosis for stroke recovery are unknown.
"A big challenge in treating stroke is understanding how other health conditions affect recovery," said Craig Brown, a neuroscientist in UVic's Division of Medical Sciences "Many diseases increase the chances of having a stroke, and they also limit recovery. Diabetes is one of these diseases, affecting millions in Canada. Much like a poker hand, the unique collection of health concerns a patient holds in their hand likely dictates how they should be treated."

The reasons behind the poorer prognosis for stroke recovery are unknown. However Brown's neurobiology lab is providing new clues.

"What we've found is that diabetic mice have leakier blood vessels in the brain after stroke than mice without diabetes. These leakier vessels lead to greater movement of proteins and other damaging elements of blood plasma into the brain, a process that is normally regulated in a strict manner to protect brain health," he explains.

The study traces the cause of leaky vessels to excessive vascular endothelial growth factor (VEGF) signaling, which regulates the growth and permeability of blood vessels. Fortunately, several drugs, known as VEGF inhibitors, have been developed over the last few decades to block cancerous tumours from growing new blood vessels and spreading.

Brown's lab used one of these cancer drugs in mouse models to see if they could reduce blood vessel leakage and the damaging effects of stroke.

The treatment not only helped reduce the leakiness of blood vessels, but it also prevented the loss of neural connections and improved the recovery of sensory-motor function-a discovery that could lead to better recovery rates for diabetic patients.

Quite surprisingly, however, the same treatment had no benefits in non-diabetic mice, suggesting that when it comes to betting on a stroke treatment, you really have to know what cards you're holding.

Source: University of Victoria
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
DEC 20, 2019
Drug Discovery & Development
DEC 20, 2019
Drug Repurposing May Provide Hope for Deadly Childhood Seizure Disorder
The life-threatening and treatment-resistant seizure disorder among children known as the ‘Dravet Syndrome’ may soon have new safe and effectiv...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
FEB 28, 2020
Cannabis Sciences
FEB 28, 2020
Pharmaceutical CBD Better for Epilepsy than Artisanal CBD
New research has found that children and teenagers suffering from epilepsy had significantly better seizure control when treated with pharmaceutical cannab...
MAR 15, 2020
Genetics & Genomics
MAR 15, 2020
Insight Into Neuronal Growth and Memory Formation
Now scientists have learned more about the transport of mRNA in neurons, and the storage and formation of memories....
Loading Comments...